



Date : January 12, 2004

Our Docket : SHX 333

Group Art Unit:

Examiner :

For : USE OF GLYCYRRHIZIN AND ITS DERIVATIVES AS MCP-1 PRODUCTION INHIBITORS

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56, 1.97, and 1.98

Applicants are submitting this Information Disclosure Statement pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98 to disclose to the U.S. Patent and Trademark Office the patents, publications, applications, and/or other references listed on the enclosed, completed PTO-1449 form(s). The filing of this Information Disclosure Statement should not be construed as a representation that a search has been made or as an admission that the listed references are prior art for this application. Applicants respectfully request that the listed references be expressly considered during prosecution of the application, and that the references be made of record therein and appear among the “references cited” on any patents issuing therefrom.

CONTENT OF DISCLOSURE

This Information Disclosure Statement includes (1) one page of PTO-1449 forms, and (2) a legible copy of each foreign and non-patent reference, if any, listed on the form(s). However, because this application was filed on or after July 1, 2003, no copies of U.S. patents or published U.S. patent applications are included.

TIMING OF DISCLOSURE / FEE INFORMATION

This Information Disclosure Statement is being filed either (1) within three months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. § 1.53(d), or (2) within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application. Therefore, in accordance with 37 C.F.R. § 1.97(b), no fee or statement under 37 C.F.R. § 1.97(e) is required.

Please contact the undersigned with any questions or comments regarding this Information Disclosure Statement.


CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on January 12, 2004.


George Painter

Respectfully submitted,

KOLISCH HARTWELL, P.C.


Anton E. Skaugset
Registration No. 38,617
Customer No. 23581
520 S.W. Yamhill Street, Suite 200
Portland, Oregon 97204
Telephone: (503) 224-6655
Facsimile: (503) 295-6679
Attorney/Agent for Applicants

SHEET 1 OF 1

INFORMATION DISCLOSURE CITATION IN AN APPLICATION		DOCKET NUMBER SHX 333		APPLICATION NUMBER 10/694,616		
		APPLICANTS Fujio Suzuki et al.				
		FILING DATE October 23, 2003		GROUP ART UNIT		
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FIL. DATE IF APPROP.
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
OTHER DOCUMENTS						
	Karpus et al., "Differential CC Chemokine-Induced Enhancement of T Helper Cell Cytokine Production," <i>Journal of Immunology</i> , Vol. 158 ('997), pp. 4129-4136. •					
	Vicenzi et al., "Divergent Regulation of HIV-1 Replication in PBMC of Infected Individuals by CC Chemokines: Suppression by RANTES, MIP-1 α , and MCP-3, and Enhancement by MCP-1," <i>Journal of Leukocyte Biology</i> , Vol. 68 (2000), pp. 405-412. •					
	Karpus et al., "Monocyte Chemotactic Protein 1 Regulates Oral Tolerance Induction by Inhibition of T Helper Cell 1-Related Cytokines," <i>The Journal of Experimental Medicine</i> , Vol. 187 (1998), pp. 733-741. •					
	Sozzani et al., "Interleukin 10 Increases CCR5 Expression and HIV Infection in Human Monocytes," <i>The Journal of Experimental Medicine</i> , Vol. 187 (1998), pp. 439-444. •					
	Gu et al., "Control of T _H 2 Polarization by the Chemokine Monocyte Chemoattractant Protein-1," <i>Nature</i> , Vol. 404, pp. 407-411. •					
EXAMINER			DATE CONSIDERED			